학술논문
GALIPDIA study: Reaching lipid targets in a population with type 2 diabetes (T2DM) from the Northwest of Spain.
Document Type
Academic Journal
Author
Villar-Taibo R; Division of Endocrinology, University Clinical Hospital of Santiago de Compostela, C/ Choupana, s/n, 15706 Santiago de Compostela, Spain; Universidade de Santiago de Compostela, Santiago de Compostela, Spain.; Fernández-Rodríguez E; Division of Endocrinology, University Clinical Hospital of Ourense, C/ Ramon Puga Noguerol, 54, 32005 Ourense, Spain.; Tejera-Pérez C; Division of Endocrinology, University Clinical Hospital of Ferrol, Avda. de la Residencia S/N, 15405 Ferrol, A Coruña, Spain; Epigenomics in Endocrinology and Nutrition Group, Instituto de Investigacion Sanitaria de Santiago (IDIS), C/ Choupana, s/n, 15706 Santiago de Compostela, Spain. Electronic address: cristina.tejera.perez@sergas.es.; Díaz-Ortega C; Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Division of Endocrinology, University Clinical Hospital of Ourense, C/ Ramon Puga Noguerol, 54, 32005 Ourense, Spain.; Sánchez-Sobrino P; Division of Endocrinology, University Clinical Hospital of Montecelo, C/ Mourente, s/n, 36071 Pontevedra, Spain.; Palmeiro-Carballeira R; Division of Endocrinology, University Clinical Hospital of Vigo, Estrada de Clara Campoamor, 341, 36213 Vigo, Pontevedra, Spain.; Rodríguez-Novo N; Division of Endocrinology, University Clinical Hospital of Lugo, C/ Doctor Ulises Romero, 1, 27003 Lugo, Spain.; Rodríguez-Carnero G; Division of Endocrinology, University Clinical Hospital of Santiago de Compostela, C/ Choupana, s/n, 15706 Santiago de Compostela, Spain; Universidade de Santiago de Compostela, Santiago de Compostela, Spain.; Pinal-Osorio I; Division of Endocrinology, University Clinical Hospital of Ourense, C/ Ramon Puga Noguerol, 54, 32005 Ourense, Spain.; Cotovad-Bellas L; Division of Endocrinology, University Clinical Hospital of Ferrol, Avda. de la Residencia S/N, 15405 Ferrol, A Coruña, Spain.; Díaz-Trastoy O; Division of Endocrinology, University Clinical Hospital of Montecelo, C/ Mourente, s/n, 36071 Pontevedra, Spain.; Mantiñán-Gil B; Division of Endocrinology, University Clinical Hospital of Vigo, Estrada de Clara Campoamor, 341, 36213 Vigo, Pontevedra, Spain.; Álvarez-Castro P; Division of Endocrinology, University Clinical Hospital of Lugo, C/ Doctor Ulises Romero, 1, 27003 Lugo, Spain.; Andújar Plata P; Division of Endocrinology, University Clinical Hospital of Santiago de Compostela, C/ Choupana, s/n, 15706 Santiago de Compostela, Spain.; Seoane-Cruz I; Division of Endocrinology, University Clinical Hospital of Ourense, C/ Ramon Puga Noguerol, 54, 32005 Ourense, Spain.; Prieto-Tenreiro A; Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Division of Endocrinology, University Clinical Hospital of Ferrol, Avda. de la Residencia S/N, 15405 Ferrol, A Coruña, Spain.; Argüeso Armesto R; Division of Endocrinology, University Clinical Hospital of Lugo, C/ Doctor Ulises Romero, 1, 27003 Lugo, Spain.; Fernández-Pombo A; Division of Endocrinology, University Clinical Hospital of Santiago de Compostela, C/ Choupana, s/n, 15706 Santiago de Compostela, Spain; Universidade de Santiago de Compostela, Santiago de Compostela, Spain.; Sánchez-Bao A; Division of Endocrinology, University Clinical Hospital of Ferrol, Avda. de la Residencia S/N, 15405 Ferrol, A Coruña, Spain.; Vidal-Casariego A; Division of Endocrinology, University Clinical Hospital of A Coruña, C/ Xubias de Arriba, 84, 15006 A Coruña, Spain.
Source
Publisher: Country of Publication: Spain NLM ID: 101717565 Publication Model: Print Cited Medium: Internet ISSN: 2530-0180 (Electronic) Linking ISSN: 25300180 NLM ISO Abbreviation: Endocrinol Diabetes Nutr (Engl Ed) Subsets: MEDLINE
Subject
Language
English
Abstract
Aim: To assess the degree of compliance with the European ESC/EAS 2016 and 2019 dyslipidaemia guidelines in patients with type 2 diabetes mellitus (T2DM).
Methods: Multicentre retrospective cross-sectional study, conducted in 380 adults with T2DM and dyslipidaemia in 7 Spanish health areas.
Inclusion Criteria: minimum follow-up of one year in Endocrinology Units, at least one visit in 2020 and a lipid profile measurement in the last 3 months.
Exclusion Criteria: familial hypercholesterolaemia, recent hospitalisation, active oncological pathology and dialysis.
Results: According to the 2016 and 2019 guidelines the majority of patients were classified as being at very high cardiovascular risk (86.8% vs. 72.1%, respectively). LDL-c compliance was adequate in 62.1% of patients according to the 2016 guidelines and 39.7% according to the 2019 guidelines (p<0.001). Clinical conditions such as history of cardiovascular disease and therapy-related aspects (use of statins, especially high-potency statins, combination therapies and good adherence) were significantly associated with greater achievement of lipid targets.
Conclusion: There is a discrepancy between dyslipidaemia guideline recommendations and the reality of lipid control in patients with T2DM, despite most of these patients being at very high cardiovascular risk. Strategies to optimise lipid-lowering treatments need to be implemented.
(Copyright © 2022 SEEN and SED. Published by Elsevier España, S.L.U. All rights reserved.)
Methods: Multicentre retrospective cross-sectional study, conducted in 380 adults with T2DM and dyslipidaemia in 7 Spanish health areas.
Inclusion Criteria: minimum follow-up of one year in Endocrinology Units, at least one visit in 2020 and a lipid profile measurement in the last 3 months.
Exclusion Criteria: familial hypercholesterolaemia, recent hospitalisation, active oncological pathology and dialysis.
Results: According to the 2016 and 2019 guidelines the majority of patients were classified as being at very high cardiovascular risk (86.8% vs. 72.1%, respectively). LDL-c compliance was adequate in 62.1% of patients according to the 2016 guidelines and 39.7% according to the 2019 guidelines (p<0.001). Clinical conditions such as history of cardiovascular disease and therapy-related aspects (use of statins, especially high-potency statins, combination therapies and good adherence) were significantly associated with greater achievement of lipid targets.
Conclusion: There is a discrepancy between dyslipidaemia guideline recommendations and the reality of lipid control in patients with T2DM, despite most of these patients being at very high cardiovascular risk. Strategies to optimise lipid-lowering treatments need to be implemented.
(Copyright © 2022 SEEN and SED. Published by Elsevier España, S.L.U. All rights reserved.)